Celgene
NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing Price on November 22, 2019
CELG Articles
There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend Monitor.
Published:
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.
Published:
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Published:
Celgene released mixed first-quarter results before the markets opened Thursday and shares were down in early trading.
Published:
ThinkstockCelgene Corp. (NASDAQ: CELG) is scheduled to release its first-quarter financial results before the markets open Thursday. Thomson Reuters has consensus estimates of $1.06 in earnings per...
Published:
Last Updated:
The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Celgene is one of the world's top biotech stocks now, and its market cap is nearly $100 billion. The company has made a new investment in a stem cell company in Australia.
Published:
The March 31 short interest data have been compared with the March 13 figures, and for most of the selected biotech stocks, short interest has increased.
Published:
The March 13 short interest data in top biotechs have been compared with the end of February figures, and across the board all the selected stocks have seen their short interest increase.
Published:
Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.
Published:
24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with the mid-February figures. Across the board, all the selected stocks have seen...
Published:
A big part of the Nasdaq is biotech, and a new report from Cowen details the stocks that big money managers love and are staying with.
Published:
The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Celgene has announced that the FDA expanded the existing indication for Revlimid in conjunction with dexamethasone.
Published:
Last Updated:
Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid pipelines and, most importantly, earnings.
Published: